SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / August 3, 2023 / CAGE Bio, Inc. hereinafter "CAGE Bio" a biotechnology company focused on developing innovative drug therapies for localized treatment of immunodermatological disorders, today announced positive results from its randomized, vehicle controlled, phase 2 study evaluating the safety and efficacy of CGB500, an ionic liquid... Lire le communiqué |